Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes.

Pulkkinen, Arto; Viitanen, Laura; Kareinen, Anu; Lehto, Seppo; Laakso, Markku

doi:10.2337/diacare.23.6.864b

Cited by 15 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is somewhat surprising that such biological changes seen with the Ser 82 allele have not been identified in clinical studies of the G82S variant in population studies, including macrovascular disease of both diabetic and non-diabetic subjects and diabetic microvascular disease (retinopathy or nephropathy) [91,[97][98][99]. Although most of these studies are in relatively small study populations, even a large prospective study of the G82S polymorphism in the Framingham Offspring Study did not reveal any associations with disease [100].…”

Section: Coding Change Polymorphisms In the Rage Gene: G82smentioning

confidence: 84%

RAGE: a novel biological and genetic marker for vascular disease

2009

View full text Add to dashboard Cite

RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.

show abstract

Section: Coding Change Polymorphisms In the Rage Gene: G82smentioning

confidence: 84%

RAGE: a novel biological and genetic marker for vascular disease

2009

View full text Add to dashboard Cite

show abstract

“…First, we found that the frequency of the 82S allele in patients with CAD (without T2DM: 21AE3% and with T2DM: 19AE3%) is similar to other Chinese with CAD and T2DM (21AE2-22AE7%), 18,19 while the frequency is higher when compared to Caucasian patients with CAD (UK with T2DM: 3%; Finnish: without T2DM 6% and with T2DM 7%; American Caucasian: SS + GS genotype 6AE8%) 13,14,16 or Korean male patients with CAD (13%). First, we found that the frequency of the 82S allele in patients with CAD (without T2DM: 21AE3% and with T2DM: 19AE3%) is similar to other Chinese with CAD and T2DM (21AE2-22AE7%), 18,19 while the frequency is higher when compared to Caucasian patients with CAD (UK with T2DM: 3%; Finnish: without T2DM 6% and with T2DM 7%; American Caucasian: SS + GS genotype 6AE8%) 13,14,16 or Korean male patients with CAD (13%).…”

Section: Discussionmentioning

confidence: 59%

“…4 Among them, the G82S polymorphism (rs2070600) in exon 3 was the first to be identified as such. [13][14][15][16] However, in Asian subjects with higher frequency of the 82S allele (approximately 20%), the association between the G82S variant and the presence or severity of coronary artery disease (CAD) remains controversial. 13 The glycine-to-serine change at position 82 occurs proximal to an N-linked glycosylation site (position 81) and in the ligand-binding V-domain of AGER, suggesting that this variant may affect AGER function.…”

Section: Introductionmentioning

confidence: 99%

“…In Caucasian population where the G82S polymorphism only occurs with a prevalence of approximately 5%, no associations between the G82S and macrovascular disease have been found. [13][14][15][16] However, in Asian subjects with higher frequency of the 82S allele (approximately 20%), the association between the G82S variant and the presence or severity of coronary artery disease (CAD) remains controversial. [17][18][19][20] The aim of this study is to evaluate the association between G82S variant and the severity of CAD with or without type 2 diabetes mellitus (T2DM) in Chinese Han population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of AGER gene G82S polymorphism with the severity of coronary artery disease in Chinese Han population

Wang

Feng

Xie

et al. 2011

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Several studies have addressed whether the polymorphism is associated with risk of micro-or macro-vascular disease in type I or type II diabetes [160,161,163,164,168,169]. Prevost et al found that 82Ser is significantly associated with risk of developing advanced nephropathy in Caucasian type I diabetic patients [160], whilst Kumaramanickavel et al found it was significantly associated with a low risk of developing diabetic retinopathy in Asian Indian patients who have type II diabetes [169].…”

Section: Rage: Glycine 82 Serine Polymorphismmentioning

confidence: 96%

Rheumatoide Arthritis: Zusammenhänge zwischen kardiovaskulären Erkrankungen und dem "Advanced Glycation End Product Receptor"

Carroll

Hannawi

Marwick

et al. 2006

Wien Med Wochenschr

View full text Add to dashboard Cite

Cardiovascular (CV) disease is increased in patients with chronic inflammatory disease, including rheumatoid arthritis (RA). Furthermore it has become clear at a pathophysiological level, that atherosclerosis has striking similarities with autoimmune disease. This realization has come at a time of paradigm shift in how rheumatologists manage RA, with the availability of biological agents targeting key inflammatory cytokines. This review will focus on the possible causes of increased vascular disease in RA, including the role of traditional CV risk factors. Mechanisms potentially at play, such as C-reactive protein (CRP), altered coagulation, and cyclooxygenase (COX)-2 inhibitors will be covered in brief. The receptor for advanced glycation end products (RAGE) has been identified as a candidate molecule influencing response to ongoing inflammation and autoimmunity. There will be a focus on the role of RAGE in CV disease and RA. As has been the case with many novel molecules, functional polymorphisms are thought to alter disease expression and assist us in coming to terms with the biological activities of the parent molecule. The review will conclude with a discussion of the potential role of the RAGE Glycine 82 Serine polymorphism.

show abstract

Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes.

Cited by 15 publications

References 0 publications

RAGE: a novel biological and genetic marker for vascular disease

RAGE: a novel biological and genetic marker for vascular disease

Association of AGER gene G82S polymorphism with the severity of coronary artery disease in Chinese Han population

Rheumatoide Arthritis: Zusammenhänge zwischen kardiovaskulären Erkrankungen und dem "Advanced Glycation End Product Receptor"

Contact Info

Product

Resources

About